Updated Jul 16, 2026
QUAY STEVEN C is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market purchases: $10K.
Steven C. Quay is the President and CEO of Atossa Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing therapies for breast cancer and COVID-19. He has extensive experience in the biotechnology sector and has held various leadership roles in the industry.
| Role | Insider |
|---|---|
| Notability | 50/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-31 | ATOS | ATOSSA THERAPEUTICS, INC. | A — Grant or award | 65.0K | $0.00 | |
| 2026-01-30 | ATOS | ATOSSA THERAPEUTICS, INC. | A — Grant or award | 331.7K | $0.00 | |
| 2026-01-22 | ATOS | ATOSSA THERAPEUTICS, INC. | A — Grant or award | 325.2K | $0.00 | |
| 2025-05-21 | ATOS | ATOSSA THERAPEUTICS, INC. | P — Open-market purchase | 11.2K | $0.88 | $10K |
Steven C. Quay is the President and CEO of Atossa Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing therapies for breast cancer and COVID-19. He has extensive experience in the biotechnology sector and has held various leadership roles in the industry.…
Recorded transactions: 1 open-market purchases ($10K) and 0 open-market sales () across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live QUAY STEVEN C profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.